menu
    • menu
    [{"orgOrder":0,"company":"TigaTx","sponsor":"Epsilogen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Acquisition","leadProduct":"EPS 401","moa":"EGFR","graph1":"Oncology","graph2":"IND Enabling","graph3":"TigaTx","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TigaTx \/ Epsilogen","highestDevelopmentStatusID":"5","companyTruncated":"TigaTx \/ Epsilogen"},{"orgOrder":0,"company":"TigaTx","sponsor":"Advanced Research Projects Agency for Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Funding","leadProduct":"TIGA-001","moa":"EGFR","graph1":"Oncology","graph2":"Preclinical","graph3":"TigaTx","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"TigaTx \/ Advanced Research Projects Agency for Health","highestDevelopmentStatusID":"4","companyTruncated":"TigaTx \/ Advanced Research Projects Agency for Health"}]

    Find Clinical Drug Pipeline Developments & Deals by TigaTx

    Menu

    TigaTx

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            TigaTx

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            TigaTx

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EPS 401

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Epsilogen

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            UK's Epsilogen acquires fellow immunoglobin biotech TigaTx

                            Details : The acquisition bolsters Epsilogen’s pipeline by adding EPS 401 (formerly TIGA-001), an anti-EGFR IgA antibody. It is being evaluated for treating neoplasms.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            April 07, 2025

                            Lead Product(s) : EPS 401

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Epsilogen

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            TigaTx

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            TigaTx

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TIGA-001

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Advanced Research Projects Agency for Health

                            Deal Size : $33.5 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            TigaTx Gets $35.5M From ARPA-H and NIH for Cancer and Infection Monoclonal Antibody

                            Details : TigaTx will use the ARPA-H funding to progress its lead program, TIGA-001, an IgA anti-EGFR neutrophil engager, which is being evaluated for the treatment of neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            December 18, 2024

                            Lead Product(s) : TIGA-001

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Advanced Research Projects Agency for Health

                            Deal Size : $33.5 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth